We are underdiagnosing this! In pts with persistently low ALP, think hypophoshatasia (HPP); these pts have recurrent poor healing fractures, may have CPPD, and have been refractory to standard OP Rx. Dr. A Abelson #ACRReview @rheumnow #ACR20 https://t.co/dVptFkYXR2

Dr. A Abelson #ACRReview @rheumnow #ACR20 Romosozumab (sclerostin Ab) for OP: 👉can be used after previous treatmt with PTH analogs 👉can be used in pts with prior radiation exposure 👉not yet approved for men. Some slides on what to choose for OP and when to choose it https://t.co/nAbOmEjx3p

from #ACR20 Dr. Abbey Abelson. There was reduction in hip fractures in the US until there was drop in reimbursement for DEXA/Bone Density. @ACRheum has been advocating on Capitol Hill to restore reimbursement. Bad policy harms, but good policy can save lives. #ACRambassador https://t.co/ARo762Vozp

ARCH study -- n~4100 Romo vs Alendronate x 12 mo Alendronate 12-24 mo RRR 38% https://t.co/d0G7x4TqUT

How do we square up bone loss and new bone formation in AS? Are these coupled? Study from the ASSERT trial showed no relationship between baseline BMD and new syndesmophyte formation in the same vertebra @RheumNow #ACR20 Abstr#1896

Study of Chinese pts on long-term GCs by Dr CC Mok: DEN >> ALN in ⬆spinal BMD & suppressing bone turnover markers after 1yr tx. No sig. diff in AEs among grps. Limits: Open-label,small ss,short tx dur'n, not powered for fractures @RheumNow #ACR20 abs1442 https://t.co/m8mT0hMPN8

#ACRKnowledgeBowl #acr20 @rheumnow This % of bone loss is assc with a T-score -1.5 on a DXA

Re Abs#760: Bone erosions in +CCP not predictive of development of IA. You have a pt with no synovitis, but +CCP, small bone erosion on standing foot xray. Do you treat? #ACR20 @Rheumnow

Dr Hansen at 3S008 on "Bone for the Holidays": individualize the decision for drug holidays - here are the key questions: #acr20 @Rheumnow https://t.co/lMHtYW4OzE